Atypical antipsychotics for bipolar disorder : overblown or blown over? by Ng, Felicity et al.
Deakin Research Online 
Deakin University’s institutional research repository 
DDeakin Research Online  
Research Online  
This is the published version (version of record) 
of: 
 
Ng, Felicity, Dodd, Seetal and Berk, Michael 2007-07, Atypical 
antipsychotics for bipolar disorder : overblown or blown over?, 
Clinical psychopharmacology and neuroscience, vol. 5, no. 2, pp. 53-
64.   
 
Available from Deakin Research Online:  
 
http://hdl.handle.net/10536/DRO/DU:30035667 
 
Reproduced with kind permission of the copyright 
owner. 
 
 
Copyright : 2007, Korean College of Neuropsychopharmacology 
 
 
 
 
 
 
 
 
 53
Review 
Clinical Psychopharmacology and Neuroscience 2007; 5(2): 53-64 
 
ISSN 1738-1088
ⓒ 2007, Korean College of Neuropsychopharmacology
online © ML Comm
 
Atypical Antipsychotics for Bipolar Disorder: 
Overblown or Blown Over? 
 
Felicity Ng, Seetal Dodd, Michael Berk 
Department of Clinical and Biomedical Sciences, Barwon Health, University of Melbourne, Melbourne, Australia 
 
Objective：Developments in the pharmacological treatment of bipolar disorder are of much interest, as the chronicity and disability 
of the disorder become better understood, and as treatment goals have shifted to emphasise early control of illness course and 
maintenance of euthymia in addition to acute episodic remission. Atypical antipsychotics have emerged as treatment options, and 
this paper aims to review the evidence for their role in bipolar disorder.  
Methods：A MEDLINE search was conducted for publications up till October 2006.  
Results：The search yielded a number of randomised, controlled clinical trials of various atypical antipsychotics as monotherapy 
or adjunctive therapy in bipolar disorder. The majority of such trials have investigated their efficacy in acute mania, with fewer stu-
dies devoted to acute bipolar depression or maintenance treatment. There are no specific trials on mixed states, which have mainly 
been studied together with bipolar mania. The most robust evidence supports a class effect of atypical agents in the treatment 
of mania.  
Conclusions：There are placebo-controlled trials that support the efficacy of olanzapine and quetiapine in bipolar depression, and 
of olanzapine and aripiprazole as maintenance treatment. There is strong support for the role of atypical antipsychotics in bipo-
lar disorder management despite a relatively narrow literature base, chiefly for the treatment of mania. However, these findings need 
to be replicated, and further investigation is warranted to clarify their spectrum of efficacy in bipolar disorder. 
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INTRODUCTION 
 
The understanding of bipolar disorder is expanding. It 
is now believed to be more prevalent than previously con-
sidered, with a recent lifetime prevalence estimate of 3.9% 
for bipolar I and II combined,1) and is recognised for its 
preponderance of depressive and subsyndromal symp-
toms.2,3) The approach towards its treatment has also been 
refined, in reflection of new information and broadening 
pharmacological and psychosocial intervention options. 
Treatment goals are ideally remission of the index epi-
sode and maintenance of euthymia, without inducing pola-
rity switch or aggravating the illness course. Additional 
goals directed towards optimising function, facilitating 
psychological development and treating comorbidities are 
almost invariably required. Pharmacotherapy is an integral 
component of bipolar disorder management, in conjunction 
with psychotherapy, behavioural and social interventions. 
However, successful control of the illness in its stabilisa-
tion and maintenance aspects is frequently unattainable 
with monotherapy, and combination psychopharmacothe-
rapy is the more common clinical experience. In broad 
groups, lithium, anticonvulsants, antidepressants and anti-
psychotics have been the primary agents used in the treat-
ment of bipolar disorder. Whilst lithium has the most 
established evidence base for its efficacy in both poles of 
the illness and in both the acute and prophylactic settings,4) 
anticonvulsants and atypical antipsychotics are emerging 
with promising roles in the treatment matrix, without the 
controversy over potential destabilising effects that attends 
the use of antidepressants.5) Atypical antipsychotics, in 
particular, have attracted much recent research to clarify 
their indications and limitations in bipolar disorder, and are 
in the process of assuming a distinct position in the phar-
macotherapeutic array of this complex disorder.  
This paper aims to review the current state of evidence 
for the role of atypical antipsychotics in the treatment of 
bipolar disorder, and to discuss the clinical implications 
of these findings. 
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Methods 
 
A literature search up to October 2006 was conducted 
using MEDLINE. Keywords entered in various combina-
tions were bipolar disorder, mania, bipolar depression, 
depression, maintenance, trials, clinical trials, atypical an-
tipsychotics, olanzapine, risperidone, quetiapine, amisul-
pride, aripiprazole, clozapine, sertindole and ziprasidone. 
Randomised, controlled trials were selected as the primary 
source of information, but non-randomised and open-la-
belled trials were also reviewed. 
 
Results 
 
Clinical trials have generally studied individual atypical 
antipsychotics as monotherapy or in combination with 
mood stabilisers for either the manic or depressive pole 
of bipolar disorder. The current literature is weighted to-
wards the study of mania, with only a small number of 
studies devoted to bipolar depression and maintenance 
treatment. 
 
Mania 
Efficacy of olanzapine, risperidone, quetiapine, aripipra-
zole and ziprasidone in acute mania has been demonstrated 
by randomised, placebo-controlled trials (Table 1).6-21) 
Whilst some trials have studied only pure mania, others 
have included mixed states. As a whole, their results sug-
gest that anti-manic efficacy is likely to be a class effect, 
which is independent of psychosis, with early differentia-
tion of response and no evidence of treatment-emergent 
depression. Response, as defined in all these studies, refers 
to a 50% or greater reduction in total baseline Young 
Mania Rating Scale (YMRS) or Mania Rating Scale 
(MRS) scores. 
 
Aripiprazole 
Two 3-week, double-blind, randomised, placebo-con-
trolled trials have measured the efficacy of aripiprazole in 
treating acute manic or mixed episodes of bipolar disorder. 
Keck et al.8) reported a significantly greater reduction of 
YMRS scores from baseline in the aripiprazole-treated 
group (N=130) compared to the placebo-treated group 
(N=132) from day 4 onwards. Response rates at endpoint 
significantly diverged, with 40% for the aripiprazole-trea-
ted group and 19% for the placebo-treated group. In a 
second trial, 137 patients were randomised to aripiprazole 
and 135 patients to placebo. Aripiprazole was also obser-
ved to be superior to placebo from day 4 onwards, and the 
response rate at endpoint was higher for the aripiprazole-
treated group compared to placebo (53% vs 32%, p≤
0.001). Mean change in YMRS total score at endpoint 
was -12.5 for aripiprazole-treated and -7.2 for placebo-
treated patients (p≤0.001).14,22) 
Aripiprazole was compared with haloperidol in acute 
bipolar mania in a double-blind, randomised controlled 
trial over 12 weeks. Patients in manic or mixed episodes 
were randomised to treatment with aripiprazole (N=175) 
or haloperidol (N=172). The aripiprazole group showed 
a higher response rate (50.9%) than the placebo group 
(29.1%)(p<0.001) at the end of 12 weeks, but these re-
sults were confounded by the disparate continuation rates 
of the two groups (50.9% for aripiprazole, 29.1% for ha-
loperidol, p<0.001), which highlight differences in tole-
rability more strongly than in efficacy.23) 
 
Olanzapine 
The efficacy of olanzapine as monotherapy and adjunc-
tive therapy in mania has been established by several 
placebo-controlled trials. Two such trials, alike in design, 
were conducted on patients with bipolar disorder in either 
manic or mixed episode. One study randomised patients 
to receive olanzapine monotherapy (N=70) or placebo 
(N=69) over 3 weeks,19) and the other study randomised 
patients to the same treatment arms (N=55 for olanzapine 
monotherapy, N=60 for placebo) for 4 weeks.18) Both 
trials found significant score reductions on their primary 
efficacy measure, the YMRS, in the olanzapine groups 
(mean score reductions of -10.319) and -14.818)) com-
pared with placebo (-4.9 and -8.1, respectively). Res-
ponse was also significantly higher in those receiving olan-
zapine, with proportions of 48.6%19) and 64.8%,18) in 
comparison with 24.2% and 42.9% for the respective pla-
cebo groups. Subgroup analysis of the pooled results of 
both trials suggests olanzapine to be effective for both 
mixed and pure mania, independent of patient demogra-
phics and the presence or absence of psychosis.24) 
The adjunctive utility of olanzapine with mood stabi-
lisers for the treatment of mania has been demonstrated 
by a 6-week, placebo-controlled trial, in which patients 
with acute mania or mixed episodes who had only partially 
responded to two weeks of lithium or valproate mono-
therapy (YMRS total score ≥16), were randomised to 
adjunctive olanzapine (N=229) or adjunctive placebo 
(N=115). Adjunctive olanzapine was superior to adjunc-
tive placebo for the treatment of manic and mixed bipolar 
episodes in this cohort (mean change in YMRS from ba-
seline of -13.1 for adjunctive olanzapine and -9.1 for 
placebo, p=0.003). Among patients with a mixed episode, 
adjunctive olanzapine was associated with greater reduc-
tions in YMRS (-12.9 vs -7.5, p<0.001) and Hamil-
ton Depression Rating Scale (HAMD-21)(-10.3 vs -1.6, 
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p<0.001), whereas a trend favouring adjunctive olanzapine 
was observed among patients presenting with pure mania 
(-13.3 vs -10.6 on YMRS, p=0.09).17) In a post hoc 
analysis of this data, the addition of olanzapine was as-
sociated with a significantly lower suicidality score on 
HAMD within one week, compared with the placebo 
group.25) 
There have also been double-blind, randomised, con-
trolled trials comparing olanzapine with other treatments. 
In a 12-week trial, patients with bipolar mania were ran-
domised to olanzapine (N=234) or haloperidol (N=219). 
Both drugs were associated with comparable remission 
rates (52.1% vs 46.1%, p=0.15), but depressive switch 
occurred significantly more rapidly in the haloperidol 
compared to the olanzapine group.26) In the same trial, a 
significantly greater improvement in health-related quality 
of life and work status was observed for the olanzapine 
group compared to haloperidol.27) This work functional 
advantage was again observed in a 6-month, open-label 
extension of the trial.28) Compared with lithium, olanzapine 
Table 1. Randomised, placebo-controlled trials of atypical antipsychotics used as monotherapy or adjuncive therapy in acute mania 
Trial Treatment arms 
Numbers in ITT 
analysis (N) 
Duration in 
weeks 
Response  
(% of patients with ≥50%  
reduction in YMRS score) 
Mean change in  
YMRS from baseline 
Monotherapy 
Keck et al8) 
 
Sachs et al14) 
 
Tohen et al19) 
 
Tohen et al18) 
 
McIntyre et al11) 
 
 
Bowden et al6) 
 
 
Hirschfeld et al7) 
 
Khanna et al10) 
 
Smulevich et al16) 
 
 
Keck et al9) 
 
Potkin et al12) 
 
 
Aripiprazole 
Placebo 
Aripiprazole 
Placebo 
Olanzapine  
Placebo 
Olanzapine 
Placebo 
Quetiapine 
Haloperidol 
Placebo 
Quetiapine 
Lithium 
Placebo 
Risperidone 
Placebo 
Risperidone 
Placebo 
Risperidone 
Haloperidol 
Placebo 
Ziprasidone 
Placebo 
Ziprasidone 
Placebo 
 
123 
122 
136 
132 
070 
069 
054 
056 
101 
098 
100 
107 
098 
095 
127 
119 
146 
144 
153 
144 
138 
131 
066 
137 
65 
 
3 
 
3 
 
3 
 
4 
 
3 
 
 
3 
 
 
3 
 
3 
 
3 
 
 
3 
 
3 
 
40c 
19 
53d 
32 
48.6c 
24.2 
65a 
43 
42.6 
56.1b 
35.0 
53.3d 
53.1d 
27.4 
43b 
24 
73d 
36 
48b 
47 
33 
n/a 
n/a 
46a 
29 
 
0-8.2c 
0-3.4 
-12.5d 
0-7.2 
-10.3a 
`0-4.9 
-14.8d 
0-8.1 
-12.3b 
-15.7d 
0-8.3 
-14.6d 
-15.2d 
0-6.7 
-10.6d 
0-4.8 
-22.7d 
-10.5 
-15.1d 
-13.9d 
0-9.4 
-12.4c* 
0-7.8 
-11.1b* 
0-5.6 
Adjunctive therapy 
Tohen et al17) 
 
Sachs et al13) 
 
Yatham et al21,32) 
 
Sachs et al15) 
 
 
Yatham et al20) 
 
Olanzapine 
Placebo 
Quetiapine 
Placebo 
Quetiapine 
Placebo 
Risperidone 
Haloperidol 
Placebo 
Risperidone 
Placebo 
 
220 
114 
081 
089 
185 
185 
051 
050 
047 
069 
073 
 
6 
 
3 
 
3 
 
3 
 
 
3 
 
67.7d 
44.7 
54.3c 
32.6 
55.7b 
41.6 
n/a 
n/a 
n/a 
59a 
41 
 
-13.1c 
0-9.1 
-13.8a 
0-9.9 
-15.3a 
-12.2 
-14.3b 
-13.4a 
0-8.2 
-14.5 
-10.3 
ITT, Intent-to-treat; YMRS, Young Mania Rating Scale; n/a, Not available, ap<0.05 compared with placebo, bp<0.01 compared with pla-
cebo, cp≤0.005 compared with placebo, dp≤0.001 compared with placebo, *Mania Rating Scale (MRS) used 
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was at least equally effective in the treatment of acute 
mania in a 4-week trial where patients were randomised 
to either olanzapine (N=15) or lithium (N=15).29) Olan-
zapine was superior to divalproex in a 3-week study of 
hospitalised patients with acute bipolar manic or mixed 
episodes, who were randomised to olanzapine (N=125) 
or divalproex (N=123). At endpoint, mean reduction in 
YMRS scores was 13.4 for the olanzapine group and 10.4 
for the divalproex group (p<0.03). Response was seen in 
54.4% of olanzapine treated patients and in 42.3% of di-
valproex treated patients (p=0.058).30) 
In a trial of a first episode population, 77 individuals 
between the age of 15 and 28 years were randomised to 
either a combination of olanzapine and lithium or chlor-
promazine and lithium in the treatment of a first manic 
episode. The duration of the acute phase of the trial was 
8 weeks, and there was an 18 month follow up period. 
They were randomised to either olanzapine, started at 5 
mg per day, or chlorpromazine, started at 100 mg per day, 
with doses titrated according to need. All individuals were 
on concurrent treatment with lithium, serum levels between 
0.8 and 1.0. There was a significant advantage of olanza-
pine over chlorpromazine at the end of the 8 week acute 
phase of the trial on the YMRS at weeks 4 (p=0.016) and 
8 (p=0.082; Kruskal Wallis test). There was a similar 
advantage for olanzapine on the BPRS, SAPS and SANS 
at the end of 4 weeks of treatment. Discontinuation rates 
did not differ between the two groups.31) 
 
Quetiapine 
Two placebo-controlled trials of quetiapine monotherapy 
have been conducted for the treatment of acute mania. 
They had similar protocols, which entailed double-blind 
randomisation of bipolar I disorder patients in a manic 
episode to three monotherapy treatment arms over 12 
weeks, with change in YMRS score from baseline serving 
as the primary outcome measure. In the first study, patients 
were randomised to quetiapine (N=102), haloperidol (N= 
99) and placebo (N=101). The quetiapine group showed 
a significant advantage over placebo after 3 weeks (mean 
YMRS score reduction of -12.3 vs -8.3, p<0.01). At 
the end of 12 weeks, quetiapine was superior to placebo 
(-17.5 vs -9.5, p<0.001), and had similar efficacy as 
haloperidol.11) The second study randomised patients to 
quetiapine (N=107), lithium (N=98) and placebo (N= 
97). Quetiapine was superior to placebo at the end of 3 
weeks (mean YMRS score reduction of -14.6 vs -6.7, 
p<0.001) and 12 weeks (-20.8 vs -9.0, p<0.001), and 
was comparable in efficacy with lithium.6) Analysis of the 
pooled data from both studies indicated significant diffe-
rentiation of the efficacy of quetiapine over placebo from 
Day 4 until the end of 12 weeks.32) 
The efficacy of quetiapine as adjunctive treatment with 
mood stabilisers was demonstrated in two 3-week, double-
blind, parallel group trials of bipolar I disorder patients in 
a manic episode. The patients, who were already on either 
lithium or divalproex, were randomised to quetiapine or 
placebo. In the first study, reduction in YMRS scores from 
baseline at 3 weeks was significantly greater for the que-
tiapine-treated (N=91) than the placebo-treated (N=100) 
patients (-13.8 vs -9.9, p=0.021). Response and remis-
sion rates, the latter defined as YMRS score of less than 
12, were also significantly higher for quetiapine compared 
with placebo (54.3% vs 32.6%, p=0.005 and 45.7% vs 
25.8%, p=0.007).13) Data from this study were pooled 
with a second trial, conducted under identical protocols 
with the exception of a longer double-blind follow-up 
period of 6 weeks, which showed non-significant trends 
in favour of quetiapine.21,33) The combined data demon-
strated superiority of quetiapine over placebo after one 
week of treatment, which remained significant at the end 
of 3 weeks, as measured by mean YMRS score reduction 
(-15.3 vs -12.2, p<0.05). Response rate was greater in 
the quetiapine-treated patients (55.7% vs 41.6%, p<0.01) 
at end-point.  
 
Risperidone 
The efficacy of risperidone monotherapy over placebo 
in the treatment of acute mania has been observed in three 
randomised, double-blind, placebo-controlled trials. Hir-
schfeld et al.7) found significantly greater improvement 
in mean YMRS score in their risperidone-treated patients 
with pure mania (N=125) compared with placebo-treated 
patients (N=134) as early as 3 days after treatment, and 
this significant difference increased at the 3-week end-
point (-10.6 vs -4.8, p<0.001). Efficacy of onset early 
and comparable magnitude was also reported by Khanna 
et al.10) In their cohort of bipolar I patients presenting with 
a manic or mixed episode, those randomised to risperi-
done monotherapy (N=146) showed significantly greater 
improvement than placebo-treated patients in mean YMRS 
score reduction from Week 1 until trial completion at Week 
3 (-22.7 vs -10.5 at end-point, p<0.001). The superio-
rity of risperidone was significant for both pure and mixed 
mania, and for those with and without psychotic features. 
A 9-week, open-label extension trial was conducted for 
patients who completed these two double-blind trials, and 
found further significant improvements for both those who 
continued or switched to risperidone.34) A third study ran-
domised patients with bipolar mania to risperidone (N= 
154), haloperidol (N=144) and placebo (N=140) mono-
therapy for 3 weeks, which was followed by a 9-week 
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double-blind phase comparing risperidone with haloperidol. 
At the end of the first 3-week phase, mean YMRS score 
reductions were significantly greater for the risperidone 
group compared with placebo (-15.1 vs -9.4, p<0.001), 
but differences between risperidone and haloperidol were 
non-significant. In the 9-week continuation phase, both 
treatment groups showed further mean reductions in 
YMRS scores from baseline (-28.7 for risperidone and 
-27.3 for haloperidol).16) 
In a 4-week, double-blind, randomised controlled trial 
comparing risperidone (N=15), lithium (N=15) and ha-
loperidol (N=15) in hospitalised patients with acute ma-
nia, risperidone showed equivalent efficacy as lithium and 
haloperidol.35) Extrapyramidal side effects from risperidone 
were noted to occur as commonly as haloperidol in this 
study, when a fixed dose of 6 mg per day of risperidone 
was used. However, this was less frequently encountered 
in risperidone-treated than haloperidol-treated patients 
when lower doses were used.16) 
The utility of risperidone as adjunctive treatment with 
mood stabilisers for acute mania has support from open-
labelled studies,36-39) and has been further substantiated 
by double-blind, randomised, placebo-controlled trials. In 
one study, bipolar patients in manic or mixed episodes who 
were treated with lithium or divalproex, were randomised 
to receive adjunctive risperidone (N=52), haloperidol 
(N=53) or placebo (N=51) for 3 weeks. Significant 
improvements from baseline YMRS scores were observed 
at end-point for patients receiving adjunctive risperidone 
and haloperidol compared to those receiving lithium or 
divalproex alone (mean reductions on YMRS of -14.3, 
-13.4 and -8.2, respectively).15) In an open-labelled, 
10-week continuation phase of this study, patients were 
treated with risperidone in conjunction with a mood sta-
biliser. Significant further improvement was observed for 
the cohort, which showed a remission rate of 79% at the 
end of the trial, with remission defined as YMRS ≤12.40) 
A second placebo-controlled study randomised patients 
with manic or mixed episodes to adjunctive treatment over 
3 weeks with risperidone (N=75) or placebo (N=75), 
in addition to treatment with lithium, divalproex or carba-
mazepine. A non-significantly greater mean YMRS score 
reduction was found at end-point for the risperidone group 
compared with placebo (-14.5 vs -10.3), although the 
response rate was significantly greater for the risperidone 
group (59% vs 41%, p<0.05). It was notable that rispe-
ridone plasma concentrations were 40% lower in the sub-
group receiving carbamazepine, and the differences in 
primary outcome measures reached significance in favour 
of the risperidone group when carbamazepine-treated pa-
tients were excluded from analysis.20) 
Ziprasidone 
Ziprasidone monotherapy in bipolar mania was investi-
gated by two 3-week, double-blind, randomised, placebo-
controlled trials of similar designs. In the earlier trial, 
patients with bipolar I disorder in manic or mixed episodes 
were randomised to ziprasidone (N=140) or placebo 
(N=70). Improvement, as measured by reduction in Ma-
nia Rating Scale (MRS) scores, was observed within 2 
days and was significantly greater in ziprasidone-treated 
than placebo-treated patients at end-point (mean MRS 
score reduction was -12.4 vs -7.8, p<0.005).9) The sub-
sequent trial had sample sizes of 137 patients in the zi-
prasidone and 65 patients in the placebo groups. Similar 
efficacy of ziprasidone from Day 2 until end-point was 
reported (mean score reduction on MRS at end-point was 
-11.1 for ziprasidone and -5.6 for placebo, p<0.01).12) 
One randomised, placebo-controlled trial studied the 
adjunctive efficacy of ziprasidone. In this 3-week trial, 
hospitalised patients with bipolar mania received either 
adjunctive ziprasidone (N=102) or placebo (N=103), in 
addition to treatment with lithium. Although significantly 
greater improvement was seen in ziprasidone-treated pa-
tients at day 4, improvements were not significantly dif-
ferent between the two groups at endpoint.41) 
 
Amisulpride and Clozapine 
No randomised, controlled data were available for the 
efficacy of amisulpride and clozapine in mania, but open-
labelled trials have been conducted. 
In a small, open-labelled, 6-week study comprising of 
20 patients with bipolar mania, amisulpride was admini-
stered but established mood stabilisers were allowed to be 
continued without dose alterations. Significant improve-
ment was found as measured using the YMRS, HAMD 
and the Clinical Global Impressions Scale for Bipolar Dis-
order, Modified (CGI-BP-M).42) 
The efficacy of clozapine in treating and preventing ma-
nia has been supported by case series,43) retrospective44) 
and open-labelled studies,45,46) which have mostly focussed 
on treatment-resistant populations. In their prospective, 13-
week, open-labelled trial of clozapine monotherapy in 25 
patients with treatment-resistant mania, Calabrese et al.45) 
reported marked improvement on YMRS, although bene-
fits were differentially in favour of those with a bipolar 
rather than a schizoaffective disorder diagnosis and those 
with non-rapid-cycling rather than rapid-cycling course. A 
12-week, open-labelled trial of clozapine monotherapy 
in 22 patients with treatment-resistant bipolar psychotic 
mania also reported efficacy, with mean improvements of 
56.7%, 56.6% and 39.1% on the Brief Psychiatric Rating 
Scale (BPRS), YMRS and CGI, respectively.46) A rando-
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mised, open-labelled study investigated adjunctive cloza-
pine (N=19) compared with treatment as usual (N=19) 
for patients with treatment-resistant schizoaffective or bi-
polar disorder with a history of mania. After one year, 
significant differences were found on global, mania, psy-
chotic symptoms and involuntary movement rating scales, 
but not on HAMD.47) Naturalistic studies have also pro-
vided support for the utility of clozapine in treatment-
resistant bipolar disorder.48,49) 
 
Bipolar Depression 
Open-labelled studies have suggested efficacy of olan-
zapine,50) quetiapine51,52) and risperidone50,53) in bipolar 
depression, but there are few randomised, controlled trials 
of atypical antipsychotics in this area (Table 2).  
Data are available from two double-blind, randomised, 
placebo-controlled trials that support the efficacy of olan-
zapine and quetiapine in the treatment of acute bipolar 
depression. In their multi-centred, 8-week trial, Tohen et 
al.54) recruited patients with bipolar I disorder, depressive 
episode, who scored at least 20 on the Montgomery-
Asberg Depression Rating Scale (MADRS). They were 
randomised to receive olanzapine (N=370), olanzapine-
fluoxetine combination (N=86) or placebo (N=377). 
From Week 1 onwards, both the olanzapine and olanza-
pine-fluoxetine combination groups showed significantly 
greater improvement than the placebo group, and from 
Week 4 onwards, the olanzapine-fluoxetine combination 
group was superior to the olanzapine group. At end-point, 
the mean reductions from baseline in MADRS scores were 
-11.9, -15.0 and -18.5 for the placebo, olanzapine and 
olanzapine-fluoxetine combination, respectively. Response 
rate, defined as ≥50% reduction in MADRS score, was 
30.4% for placebo, 39.0% for olanzapine and 56.1% for 
olanzapine-fluoxetine. Remission, defined as a MADRS 
score ≤12 at end-point, was achieved by 24.5%, 32.8% 
and 48.8% of the respective groups. Times to response 
and remission were shortest for the olanzapine-fluoxe-
tine combination, followed by olanzapine then placebo. 
Adverse effects of the active treatments were similar, 
except for higher rates of nausea and diarrhoea for the 
olanzapine-fluoxetine combination. Of particular interest, 
treatment-emergent mania did not differ among the three 
groups during the 8-week period. In the 6-month, open-
label extension to this trial, patients were continued on 
either olanzapine, the olanzapine-fluoxetine combination, 
or were switched from one to the other. Among those who 
had not entered remission, the majority achieved remission 
during the extension trial, and those who had already remit-
ted maintained their MADRS scores at end-point, with the 
exception of the switch group, which showed an increase 
of 2.3 (p=0.02).55) 
In the BOLDER I study, Calabrese et al.56) conducted 
an 8-week, randomised, placebo-controlled trial of que-
tiapine in patients with bipolar I (N=360) or bipolar II 
(N=182) disorder who were in a major depressive epi-
sode. The patients were randomly allocated to receive 
quetiapine at 300 mg daily dose (N=172), 600 mg daily 
Table 2. Randomised, controlled trials of atypical antipsychotics in bipolar depression 
Trial Treatment arms Numbers in ITT analysis (N)
Duration in
weeks 
Response  
(% of patients with ≥50%  
reduction in MADRS score) 
Mean change in 
MADRS from 
baseline 
Placebo-controlled 
Tohen et al54) 
 
 
Calabrese et al56) 
 
 
Amsterdam and Shults59) 
 
Olanzapine 
Olanzapine/fluoxetine 
Placebo 
Quetiapine 300 mg 
Quetiapine 600 mg 
Placebo 
Fluoxetine 
Olanzapine 
Olanzapine/fluoxetine 
Placebo 
 
351 
082 
355 
172 
170 
169 
008 
008 
009 
009 
 
08 
 
 
08 
 
 
08 
 
39.0a 
56.1b 
30.4 
57.6b 
58.2b 
36.1 
n/a 
n/a 
n/a 
n/a 
 
-15.0b 
-18.6b 
-11.9 
-16.4b 
-16.7b 
0-8.5 
n/a 
n/a 
n/a 
n/a 
Non-placebo-controlled 
Brown et al60) 
 
Shelton and Stahl61) 
 
Olanzapine/fluoxetine 
Lamotrigine 
Adjunctive(to mood stabiliser):
Risperidone 
Paroxetine 
Risperidone/paroxetine 
 
205 
205 
 
010 
010 
010 
 
07 
 
 
12 
 
68.8 
59.7 
 
n/a 
n/a 
n/a 
 
-14.9c 
-12.9 
 
0-4.2 
0-7.9 
0-5.8 
ITT, Intent-to-treat; MADRS, Montgomery-Asberg Depression Rating Scale; n/a, Not available, ap<0.05 compared with placebo, bp≤0.001
compared with placebo, cp=0.002 between comparators 
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dose (N=170), or placebo (N=169). Both quetiapine 
groups were superior to placebo from Week 1 onwards, 
and mean reductions in MADRS scores at end-point were 
-10.3 for placebo, -16.4 for quetiapine 300 mg/day, and 
-16.7 for quetiapine 600 mg/day. Response rates for both 
quetiapine groups were similar (57.6% for 300 mg/day 
and 58.2% for 600 mg/day), and significantly greater than 
placebo (36.1%, p<0.001), although significant differen-
tiation of responders was observed earlier (Week 1) for 
those receiving 600 mg/day quetiapine than those on 300 
mg/day (Week 2). The quetiapine groups shared the same 
remission rate (52.9%), which was significantly higher 
than placebo (28.4%)(p<0.001). Quetiapine was well-
tolerated, and treatment-emergent mania rates did not sig-
nificantly differ between the quetiapine and placebo groups 
(3.2% and 3.9%, respectively). The effect size was 0.81 
for 600 mg/day quetiapine and 0.67 for 300 mg/day que-
tiapine. In the bipolar I subgroup, effect sizes were 1.09 
for the 600 mg/day group and 0.91 for the 300 mg/day 
group, whereas the corresponding figures were 0.39 and 
0.28 in the bipolar II subgroup. These figures compared 
with an effect size of 0.31 for the olanzapine monothe-
rapy trial.54) Secondary analysis of data from this trial also 
found significant anxiety reduction associated with quetia-
pine monotherapy in the bipolar I subgroup.57) Efficacious 
results of quetiapine monotherapy have been replicated 
in the recently completed 8-week, double-blind BOLDER 
II study (N=509), which reported significant end-point 
mean MADRS reductions for both the 300 mg/day and 600 
mg/day dosages of quetiapine, with respective effect sizes 
of 0.61 and 0.54, and no differentiation of efficacy between 
the two dosages.58) 
A small placebo-controlled trial of olanzapine, fluoxe-
tine and the olanzapine-fluoxetine combination was con-
ducted in 30 bipolar I or bipolar II disorder patients in a 
major depressive episode. Significant improvements were 
observed in all comparison groups, but no significant dif-
ferences were found among them. However, conclusions 
could not be confidently derived as the study was inade-
quately powered to detect statistical differences in effi-
cacy.59) 
Brown et al.60) compared the olanzapine-fluoxetine com-
bination with lamotrigine in a 7-week double-blind, ran-
domised, controlled trial which recruited patients with a 
diagnosis of bipolar I disorder, depressed. Although pati-
ents treated with the olanzapine-fluoxetine combination 
(N=205) demonstrated significantly greater improvement 
than those treated with lamotrigine (N=205) on the CGI, 
MADRS and YMRS, the effect sizes were small. Res-
ponse rates were similar between the two groups, but the 
olanzapine-fluoxetine combination group had a shorter 
time to response. Adverse effects were more common for 
the olanzapine-fluoxetine combination, but suicidal and 
self-injurious behaviour occurred more frequently in the 
lamotrigine group. The lack of placebo control and the 5-
week titration period for lamotrigine were two factors that 
limited the interpretation of these results. 
The adjunctive role of atypical antipsychotics has been 
investigated. A small, 12-week, double-blind, randomised, 
controlled trial compared risperidone, paroxetine and the 
combination of both in patients with a depressive phase 
of bipolar I or II disorder, who were already established 
on a mood stabiliser. They were assigned to treatment with 
risperidone plus placebo, paroxetine plus placebo, and 
risperidone plus paroxetine (N=10 for all groups). All 
groups showed modest but significant improvement, 
although they did not differentiate from one another in 
outcome.61) In the Systematic Treatment Enhancement Pro-
gram for Bipolar Disorder (STEP-BD) study, 66 patients 
with treatment-resistant bipolar depression, as defined by 
non-response to a combination of mood stabilisers plus at 
least one antidepressant, were randomised to open-label 
adjunctive treatment with lamotrigine, inositol or risperi-
done. At the end of 16 weeks, the groups did not signifi-
cantly differ in their rates of recovery, but the lamotrigine 
group had lower depression, global and functional ratings 
than the other groups.62) 
 
Maintenance 
A limited number of randomised, controlled trials has 
investigated aripiprazole monotherapy, olanzapine mono-
therapy and olanzapine adjunctive to a mood stabiliser 
as maintenance pharmacotherapy in bipolar disorder 
(Table 3). 
The prophylactic efficacy of olanzapine was demon-
strated in a study, in which patients with bipolar I disor-
der who had remitted from a manic or mixed episode 
with open-label olanzapine monotherapy were randomised 
to receive maintenance olanzapine (N=255) or placebo 
(N=136) for up to 48 weeks. Using a YMRS or HAMD 
score ≥15 or hospitalisation as markers of symptomatic 
relapse, those assigned to olanzapine had a significantly 
lower relapse rate than those assigned to placebo (46.7% 
vs 80.1%, p<0.001), which corresponded to a number 
needed to treat of 3.0 (95% confidence interval 2.3-4.1). 
The median time to symptomatic relapse into a subsequent 
mood episode was significantly longer for the olanzapine 
than the placebo group (174 days vs 22 days, p<0.001). 
This advantage appeared to apply to manic, depressive 
and mixed episodes.63,64) 
Olanzapine was compared with lithium in a 12-month 
trial, which recruited patients initially presenting with ei-
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ther a manic or mixed episode that subsequently remitted 
on open-label olanzapine and lithium. They were then 
randomised to double-blind olanzapine (N=217) or li-
thium (N=214) monotherapy. Symptomatic relapse rates 
were not significantly different between the two groups 
(30.0% for olanzapine and 38.8% for lithium). However, 
olanzapine was superior to lithium in preventing manic or 
mixed episode relapse, and the two agents were compa-
rable in preventing depressive relapse.65,66) Post hoc analy-
sis of data from this study reported significantly lower 
manic or mixed, but not depressive, relapses with olanza-
pine for those classified as having early-stage (ie 2 prior 
manic/mixed episodes) bipolar disorder.67) Comparison 
data with divalproex is also available from a 47-week 
double-blind trial of bipolar patients who presented with 
a manic or mixed episode. Olanzapine-treated patients 
(N=125) remitted earlier than divalproex-treated patients 
(N=126)(median time to remission 14 days vs 62 days, 
p<0.05) and had a greater mean reduction in YMRS score 
at end-point (-15.4 vs -12.5, p=0.03), although the 
remission rates of the groups did not significantly differ. 
Neither the recurrence rates for an affective episode nor 
the time to recurrence was significantly different between 
the olanzapine and divalproex groups.68) A post hoc ana-
lysis of this trial suggested that olanzapine and divalproex 
had similar anti-manic efficacy for both rapid and non-
rapid cycling patients, but olanzapine was superior to di-
valproex for non-rapid cycling patients.69) 
An 18-month, double-blind, placebo-controlled trial in-
vestigated the adjunctive benefits of olanzapine as bipolar 
maintenance treatment. This was an extension to a pre-
viously cited trial of adjunctive olanzapine in acute ma-
nia,17) and included patients who achieved remission with 
olanzapine plus either lithium or valproate. They were 
randomly assigned to treatment with olanzapine plus li-
thium or valproate (N=51), or placebo plus lithium or 
valproate (N=48). Time to syndromic relapse (when 
patients met diagnostic criteria for a manic, mixed or de-
pressive episode) was not significantly different for the 
two groups. However, when the less stringent criteria of 
symptomatic relapse (defined as a YMRS or HAMD-21 
score ≥15) were used, the olanzapine-treated group had 
a significantly longer time to relapse into a subsequent 
affective episode, but relapse rates did not significantly 
differ.70) Weight gain was a consistent significant treatment-
emergent event associated with olanzapine that was repor-
ted by all the above longitudinal trials.63-66,68,70) 
A single double-blind trial of aripiprazole was conducted 
in recently manic patients with bipolar I disorder. Patients 
who had been stabilised on open-label aripiprazole were 
randomised to aripiprazole (N=78) or placebo (N=83) 
for 26 weeks. The aripiprazole patients had fewer affective 
relapses than the placebo patients (25% vs 43%, p=0.013), 
and showed a significantly delayed time to relapse. How-
ever, the delay of relapse was only significant for manic 
but not depressive relapses.71,72) 
A small open-labelled study has suggested that amisul-
pride may be useful in reducing manic relapse.73) 
 
Mixed States 
The concept of mixed states is still being refined, and 
various definitions are available, including that of concur-
rent diagnostic criteria for both major depressive episode 
and mania as stipulated by the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR),74) and those 
with less stringent criteria that focus on the predominant 
affective state.75,76) In studies of atypical antipsychotic 
treatment in bipolar disorder, mixed states have mostly 
Table 3. Randomised, controlled trials of atypical antipsychotics as maintenance treatment in bipolar disorder 
Trial Treatment arms Numbers in ITT analysis (N) Duration 
Median time to 
symptomatic  
relapse in days 
Rate of  
symptomatic 
relapse (%)
Placebo-controlled 
Keck et al71) 
 
Tohen et al63)64) 
 
Tohen et al70) 
 
Aripiprazole 
Placebo 
Olanzapine 
Placebo 
Adjunctive (to lithium or valproate):
Olanzapine 
Placebo 
 
077 
083 
225 
136 
 
051 
048 
 
26 weeks
 
48 weeks
 
 
18 months
 
n/a 
n/a 
174a 
022 
 
163b 
042 
 
n/a 
n/a 
46.7a 
80.1 
 
37c 
55 
Non-placebo-controlled 
Tohen et al68) 
 
Tohen et al65,66) 
 
Olanzapine 
Divalproex 
Olanzapine 
Lithium 
 
125 
126 
217 
214 
 
47 weeks
 
12 months
 
NS 
 
NS 
 
42.4c 
56.5 
30.0d 
38.8 
ITT, Intent-to-treat; n/a, Not available; NS, Non-significant difference, ap<0.001 between comparators, bp=0.023, cNon-significant, dp=0.055
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been defined using DSM-IV-TR criteria and included with 
mania. Results from these studies have generally supported 
the efficacy of atypical antipsychotics for the acute and 
maintenance treatment of the manic and mixed episode 
cohorts,8-10,12,15,17-19,30,40) but no trial has specifically inve-
stigated those with mixed states. In a pooled data analysis 
of two placebo-controlled trials of olanzapine in acute ma-
nia, efficacy was found to be comparable between the pure 
mania and mixed episode subgroups.24) However, in a 
placebo-controlled trial comparing the olanzapine plus 
mood stabiliser combination with mood stabiliser mono-
therapy, cotherapy with olanzapine was associated with 
greater benefits for mixed than pure mania.17) 
 
Bipolar Disorder in Children and Adolescents 
Trials of atypical antipsychotics in paediatric and adoles-
cent bipolar disorder are few in number and have small 
sample sizes. The efficacy of olanzapine monotherapy,77,78) 
risperidone monotherapy78) and adjunctive risperidone79) 
in bipolar mania has been supported by open-labelled stu-
dies. 
The use of quetiapine in adolescent mania has been stu-
died in two double-blind, randomised, controlled trials. 
In comparison with divalproex, quetiapine showed similar 
reduction in YMRS scores in a 28-day study of 50 pati-
ents, but was associated with more rapid improvement and 
greater response and remission rates.80) When initiated as 
the same time as divalproex in a 6-week trial on 30 pati-
ents, the quetiapine-divalproex combination demonstrated 
significantly greater score reduction from baseline on 
YMRS and a higher response rate (83% vs 53%, p=0.05) 
than divalproex monotherapy.81) 
 
Discussion 
 
The pharmacotherapy of bipolar disorder has increased 
in complexity, as treatment goals have become more pre-
cise and involve not only acute episodic remission, but 
the prevention of subsequent episodes and tempering of 
potentially aggressive illness course. Clinically, combina-
tion therapy frequently appears necessary in addressing 
these goals, as pharmacological agents seem differentially 
efficacious for distinct poles and phases of the illness. For 
atypical antipsychotics, there is strong support for their 
role in bipolar disorder management despite a relatively 
narrow literature base. However, their inter- and intra-class 
comparative efficacies for each illness pole or phase await 
further delineation.  
There is convincing evidence of efficacy for atypical 
antipsychotics in the treatment of acute mania. As a class, 
they have demonstrated anti-manic properties that are inde-
pendent of psychosis, and have been associated with early 
improvements, often within days. For olanzapine and que-
tiapine, their efficacy in mania has been comparable to 
lithium in individual trials. The adjunctive benefits of olan-
zapine, risperidone and perhaps quetiapine have been sug-
gested by randomised controlled trials. The tolerability 
of atypical antipsychotics has generally been favourable 
in clinical trials, although the consistent reports of weight 
gain from olanzapine present concerns for its use as main-
tenance therapy.  
In bipolar depression, fewer studies of atypical antipsy-
chotics are available, and results in favour of their use 
have been less consistent. However, there is one placebo-
controlled trial for olanzapine and two for quetiapine that 
demonstrated their efficacy. The differential effect sizes 
for the quetiapine and olanzapaine monotherapy data sets 
are intriguing. If this reflects trial selection differences, 
the variable outcomes seen in many trials of agents in a 
single class across multiple trials or a true difference in 
efficacy remains uncertain. Head to head trials are needed 
to answer this more definitively.  
No increase in manic switch was reported, although the 
trial periods were only eight weeks in duration. Notably, 
the olanzapine-fluoxetine combination was superior to 
olanzapine in acute bipolar depression during the acute 
8-week study, but greater improvement was observed for 
olanzapine than the olanzapine-fluoxetine combination in 
the 24-week extension study, without apparent dissimi-
larities in manic switch rates. This raises the possibility 
that combination therapy may produce a synergistic effect 
in the short-term, but its long-term improvement trajectory 
may not substantially differ from olanzapine monotherapy. 
In maintenance phase, the existing limited evidence sup-
ports the prophylactic efficacy of olanzapine for manic, 
mixed and depressive relapses. It may be superior to li-
thium for manic or mixed relapses, and may be superior 
to divalproex in non-rapid cycling patients. These findings 
require replication. There is one trial supporting the utility 
of aripiprazole in manic but not depressive prophylaxis, 
but the generalisability of such maintenance benefits to 
other agents in the class awaits further clinical trials. 
The current evidence best supports atypical antipsycho-
tics as anti-manic agents, but the extent of their mood 
stabilising potential is yet to be fully clarified. The clini-
cal implications of such findings are significant, as alter-
native treatment options for bipolar disorder are either 
equally restricted in evidence base, as in the case of some 
novel anticonvulsants, or are associated with substantial 
side effects. Therefore, the availability of efficacious yet 
well-tolerated options is an important treatment advance. 
Furthermore, the treatment of bipolar subgroups, such as 
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the first episode, dual diagnosis, mixed states and rapid 
cycling illness, are relatively unexplored and the ability 
of atypical antipsychotics to contribute in these specific 
areas may warrant closer investigation. These agents may 
also have a distinct anxiety-reducing profile, as suggested 
by a quetiapine trial, and may prove to be an additional 
benefit in the treatment of bipolar disorder. 
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